Undersøgelse af NX-5948 i kombination med andre lægemidler hos voksne med B-celle-maligniteter
Et åbent, multicenter fase 1b/2-studie til evaluering af sikkerhed og effekt af NX-5948 i kombination med andre lægemidler hos voksne med B-celle-maligniteter
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
- How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
- The effects of bexobrutideg in the body when taken with these other treatments
- How well bexobrutideg treats CLL or SLL when taken with these other treatments
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Additional Site Contact Information
- Telefonnummer: 415-417-3418
- E-mail: clinicaltrials@nurixtx.com
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92618
- Ikke rekrutterer endnu
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rekruttering
- Rocky Mountain Cancer Centers
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33146
- Ikke rekrutterer endnu
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Ikke rekrutterer endnu
- University of Kansas Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89169
- Ikke rekrutterer endnu
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Belleville, New Jersey, Forenede Stater, 07109
- Ikke rekrutterer endnu
- New Jersey Cancer Care
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- Oncology Associates of Oregon
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Tyler, Texas, Forenede Stater, 75702
- Rekruttering
- Texas Oncology - Northeast
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ and bone marrow function
- Measurable disease by computed tomography (CT) per iwCLL
- For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
- Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
- Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
- Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
- Previously treated with a BTK degrader
- Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
- Known central nervous system (CNS) lymphoma or leukemia
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NX-5948 + venetoclax
|
Administered orally once daily as a capsule
Andre navne:
Administered orally once daily as a tablet per prescribing information |
|
Eksperimentel: NX-5948 + venetoclax + rituximab
|
Administered orally once daily as a capsule
Andre navne:
Administered orally once daily as a tablet per prescribing information Administered as an intravenous (IV) infusion per prescribing information |
|
Eksperimentel: NX-5948 + venetoclax + obinutuzumab
|
Administered orally once daily as a capsule
Andre navne:
Administered orally once daily as a tablet per prescribing information Administered as an IV infusion per prescribing information |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med behandlingsrelaterede bivirkninger
Tidsramme: Op til cirka 7 år
|
Op til cirka 7 år
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate as determined by investigator
Tidsramme: Up to approximately 7 years
|
The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR |
Up to approximately 7 years
|
|
Duration of response as determined by investigator
Tidsramme: Up to approximately 7 years
|
Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Progression-free survival as determined by investigator
Tidsramme: Up to approximately 7 years
|
Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Complete response rate as determined by investigator
Tidsramme: Up to approximately 7 years
|
The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL. |
Up to approximately 7 years
|
|
Time to response as determined by investigator
Tidsramme: Up to approximately 7 years
|
Time from the start date of study treatment to the date of the first assessment of a response |
Up to approximately 7 years
|
|
Overall survival
Tidsramme: Up to approximately 7 years
|
Time from the start date of study treatment to the date of death from any cause |
Up to approximately 7 years
|
|
Pharmacokinetic profile of NX-5948
Tidsramme: Up to approximately 1 year
|
NX-5948 concentrations in blood samples |
Up to approximately 1 year
|
|
Pharmacokinetic profile of venetoclax
Tidsramme: Up to approximately 1 year
|
Venetoclax concentrations in blood samples |
Up to approximately 1 year
|
|
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Tidsramme: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life |
Baseline and up to approximately 27 months
|
|
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Tidsramme: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes |
Baseline and up to approximately 27 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Study Director, Nurix Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Kronisk sygdom
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Leukæmi, B-celle
- Lymfom
- Leukæmi, lymfoid
- Leukæmi
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Lymfom, B-celle
- Leukæmi, lymfatisk, kronisk, B-celle
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Antistoffer, monoklonal, murint afledt
- Rituximab
- Venetoclax
- Obinutuzumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NX-5948-203
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .